Avalon CEO John Schneider presents on “The Economics of Molecular Diagnostics” at the University of California Berkeley’s School of Public Health. The lecture covered the basics of molecular diagnostics followed by a more detailed assessment of the costs and benefits of molecular diagnostics. Discussions centered around the value of diagnostics, and how payers and patients measure perceived value. The topic of “companion diagnostics” and “personalized medicine” received special attention (see related blog). Avalon Health Economics will also teach a course on similar topics at the upcoming ISPOR conference in Milan, Italy (more information).
